Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Thera CS (NQ: NTLA )

13.80 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Thera CS

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Where Intellia Therapeutics Stands With Analysts
Via Benzinga
Hereditary Angioedema Update Solidifies Intellia's Cell Therapy's Competitive Efficacy Profile: Analyst
Sunday, Intellia Therapeutics Inc (NASDAQ: NTLA) announced updated interim results from the Phase 1 portion of the ongoing  
Via Benzinga
Why Are Cruise Stocks CCL, RCL, NCLH Up Today?
Cruise stocks are on the rise Monday as investors react to a positive note to clients from JPMorgan analysts and we've got the details! 
Via InvestorPlace
BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing
Biogen (BIIB) stock is a hot topic among traders Monday as the company's share resumed trading following a halt that was in effect on Friday. 
Via InvestorPlace
Why Is Intellia (NTLA) Stock Up 5% Today?
NTLA stock is trending on social media and is up over 5%. The drugmaker reported new, positive results from its gene-edited treatment. 
Via InvestorPlace
Intellia Therapeutics Surges As CRISPR Gene-Editing Drug Potentially Cures Swelling Disease
The company is testing a treatment for hereditary angioedemia, a potentially fatal swelling disorder. 
Via Investor's Business Daily
Can This Gene-Editing Stock Deliver 10X Returns?
Buying shares of Intellia Therapeutics might be a smart move. 
Via The Motley Fool
12 Analysts Have This to Say About Intellia Therapeutics
Via Benzinga
Intellia Therapeutics: Q1 Earnings Insights
Via Benzinga
Intellia Therapeutics's Earnings Outlook
Via Benzinga
Why Intellia Therapeutics Stock Is Rising Monday
Intellia Therapeutics Inc (NASDAQ: NTLA) shares are trading higher Monday after the clinical-stage genome editing company announced data for its treatment for people living with hereditary angioedema... 
Via Benzinga
Chinook Therapeutics, Oracle And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. Chinook Therapeutics, Inc. (NASDAQ: KDNY) shares jumped 66.8% to $40.01 in... 
Via Benzinga
Wall Street Says These 2 Stocks May Double. Should You Buy Them?
Both of these stocks have declined over the past year. 
Via The Motley Fool
Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You?
The Ark Invest CEO is betting on rebounds for these beaten-down stocks. 
Via The Motley Fool
Why Intellia Therapeutics Shares Are Surging Today
Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares are up Thursday as its Q1 results surpassed estimates. The company looks forward to sharing new interim data from NTLA-2001 and NTLA-2002... 
Via Benzinga
Where Intellia Therapeutics Stands With Analysts
Via Benzinga
The 3 Most Promising Gene Editing Stocks to Buy in 2023
Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in. 
Via InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor has stumbled after a hot start to 2023, but Wood keeps adding to some of her favorite positions. 
Via The Motley Fool
3 Biotech Stocks to Watch After Johnson & Johnson’s Earnings Beat
Discover the latest picks in the biotech industry with our article on 3 biotech stocks to watch after Johnson & Johnson’s earnings beat. 
Via InvestorPlace
3 High-Growth Biotech Stocks Poised for Success in 2023
If you look for growth opportunities wherever you can find them, there are some high-growth biotech stocks that could present an opportunity 
Via InvestorPlace
2 Monster Growth Stocks That Can Double in Value, According to Wall Street
These stocks have some promising growth opportunities, but they also come with a fair amount of risk. 
Via The Motley Fool
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
Via Benzinga
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
Via Benzinga
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
3 Beaten-Down Stocks That Could Soar This Year
These stocks could enjoy big rebounds in 2023. 
Via The Motley Fool
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money
There are no guarantees that any stock will generate huge returns. But the odds look pretty good for these three growth stocks. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.